Neptune Reports Second Quarter Results

Thu Oct 13, 2011 4:01pm EDT

* Reuters is not responsible for the content in this press release.

LAVAL, Quebec, Oct. 13, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) today reports its
consolidated financial results for the three-month period ended August May 31,
2011.

Three-month Ended August 31, 2011 Financial Results

Consolidated Results

  --  Revenue increased by 6% to $4,353,000 for the three-month period ended
      August 31, 2011, up from $4,114,000 achieved during the corresponding
      period ended August 31, 2010.
  --  Consolidated EBITDA for the three-month period ended August 31, 2011
      amounted to a negative $908,000, compared to $836,000 obtained during
      the corresponding period ended August 31, 2010.
  --  Net earnings decreased to for a net loss of $1,768,000 or $0.036 per
      share for the three-month period ended August 31, 2011, compared to a
      net income of $523,000 or $0.013 per share, for the corresponding period
      ended August 31, 2010.


Revenue increased by 6% in dollar and more than 50% in quantities, EKO(TM)
representing 31%.
EBITDA negative because of significant progress in R&D activities in the
subsidiaries and more specifically Acasti's Medical Food, Onemia(TM), commercial
strategy in the USA.
Net loss because of significant progress in the R&D activities in the
subsidiaries including Acasti's Phase II study.

Nutraceutical Business Results

  --  Nutraceutical revenue increased by 7% to $4,353,000, for the three-month
      period ended August 31, 2011, up from $4,088,000 achieved during the
      corresponding period ended August 31, 2010.
  --  EBITDA from nutraceutical business for the three-month period ended
      August 31, 2011 was $650,000, compared to $1,290,000 obtained during the
      corresponding period ended August 31, 2010.
  --  Net income from nutraceutical business reached $206,000 for the
      three-month period ended August 31, 2011, compared to a net income of
      $1,079,000, for the corresponding period ended August 31, 2010.


Revenue increased by 7% in dollar and more than 50% in quantities, EKO(TM)
representing 31%.
EBITDA positive because Neptune stand alone activities are profitable.
Net income positive because Neptune stand alone activities are profitable.

Six-month Ended August 31, 2011 Financial Results

Consolidated Results

  --  Revenue increased by 4% to $8,645,000 for the six-month period ended
      August 31, 2011, up from $8,276,000 achieved during the corresponding
      period ended August 31, 2010.
  --  Consolidated EBITDA for the six-month period ended August 31, 2011
      amounted to a negative $1,075,000, compared to $1,501,000 obtained
      during the corresponding period ended August 31, 2010.
  --  Net earnings decreased to for a net loss of $3,026,000 or $0.065 per
      share for the six-month period ended August 31, 2011, compared to a net
      income of $1,017,000 or $0.025 per share, for the corresponding period
      ended August 31, 2010.


Revenue increased by 4% in dollar and more than 50% in quantities, EKO(TM)
representing 31%.
EBITDA negative because of significant progress in R&D activities in the
subsidiaries and more specifically Acasti's Medical Food, Onemia(TM), commercial
strategy in the USA.
Net loss because of significant progress in the R&D activities in the
subsidiaries including Acasti's Phase II study.

Nutraceutical Business Results

  --  Nutraceutical revenue increased by 5% to $8,636,000, for the six-month
      period ended August 31, 2011, up from $8,232,000 achieved during the
      corresponding period ended August 31, 2010.
  --  EBITDA from nutraceutical business for the six-month period ended August
      31, 2011 was $1,424,000, compared to $2,361,000 obtained during the
      corresponding period ended August 31, 2010.
  --  Net income from nutraceutical business reached $136,000 for the
      three-month period ended August 31, 2011, compared to a net income of
      $2,009,000, for the corresponding period ended August 31, 2010.


Revenue increased by 5% in dollar and more than 50% in quantities, EKO(TM)
representing 31%.
EBITDA positive because Neptune stand alone activities are profitable.
Net income positive because Neptune stand alone activities are profitable.

"The Company's revenue growth is attributable to the further penetration of the
American and European markets due to the increasing awareness and recognition of
NKO(R) and EKO(TM) superiority. Despite market increased competitiveness, the
Company has managed to maintain growth in its revenues," stated Andre Godin,
Chief Financial Officer. "The Company recorded its more significant market
penetration while increasing its NKO(R) and EKO(TM) volume sold by more than
50%," he added.

"The nutraceutical net profit demonstrates once again that Neptune
neutraceutical business is a profitable operation despite the competition
pressure on pricing. The composition of matter patent recently granted, on which
basis Neptune filed action against competition, should provide further pricing
flexibility," stated Frederic Harland, Director Finance. "It's also important to
point out that the consolidated results accounts for the increased research &
development expenses in Acasti, due to its phase II clinical trial," he added.

Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and neurological
diseases driven by consumers taking a more proactive approach to managing health
and preventing disease. The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory approval for
label health claims. Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals. Neptune's
products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component of cell
membranes and are essential for all vital cell processes. They are one of the
principal constituents of High Density Lipoprotein (good cholesterol) and, as
such, play an important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the polyunsaturated
omega-3 fatty acids EPA and DHA, which have been shown to have substantial
health benefits and which are stabilized by astaxanthin, a potent antioxidant.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical food and
prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational partner is
already initiated. The development of a prescription drug candidate is currently
in progress. Advanced clinical development and commercialization is planned to
be carried out with multinational partners.


"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services
  Provider (as that term is defined in the policies of the TSX Venture
  Exchange) accepts responsibility for the adequacy or accuracy of this
                                release."



 Statements in this press release that are not statements of historical
  or current fact constitute "forward-looking statements"  within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
Canadian securities laws. Such forward-looking statements involve known
 and unknown risks, uncertainties, and other unknown factors that could
cause the actual results of the Company to be materially different from
  historical results or from any future results expressed or implied by
    such forward-looking statements. In addition to statements which
 explicitly describe such risks and uncertainties, readers are urged to
    consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or "plans" to be uncertain
and forward-looking. The forward-looking statements contained herein are
    also subject generally to other risks and uncertainties that are
  described from time to time in the Company's reports filed with the
     Securities and Exchange Commission and the Canadian securities
                              commissions.


CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com

         CEOcast Contact:
         Dan Schustack
         +1 212-732-4300
         dschustack@ceocast.com
         www.ceocast.com

         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         bob@howardgroupinc.com
         www.howardgroupinc.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.